oXiris吸附滤器连续性肾脏替代治疗可能降低脓毒症28天死亡率:系统评价与Meta分析
该Meta分析检索11个数据库,纳入14项研究共695例脓毒症患者,评估CRRT中使用oXiris吸附滤器对其他滤器的临床结局影响。主要终点28天死亡率显著降低(OR 0.53;95%CI 0.36-0.77,p=0.001),ICU住院时间缩短(WMD -1.91;95%CI -2.56至-1.26,p<0.001),SOFA评分、去甲肾上腺素剂量、IL-6和乳酸水平及7天、14天死亡率也更低;但90天死亡率、ICU和医院死亡率及住院时间无显著差异。10项观察性研究质量中等至高(平均NOS评分7.8),4项RCT偏倚风险不明确,所有结局证据确定性低或极低,oXiris滤器的有效性仍不确定。
要点
- 脓毒症患者CRRT使用oXiris滤器较其他滤器28天死亡率降低(OR 0.53;95%CI 0.36-0.77,p=0.001)。
- oXiris组ICU住院时间缩短(WMD -1.91;95%CI -2.56至-1.26,p<0.001),SOFA评分、去甲肾上腺素剂量、IL-6和乳酸水平及7天、14天死亡率更低。
- 90天死亡率、ICU和医院死亡率及住院时间在oXiris组与其他滤器组间无显著差异。
- 所有结局证据确定性为低或极低,主要因原始研究多为观察性设计、RCT偏倚风险不明确且样本量小。
适用人群与场景
- 脓毒症患者(14项研究共695例,纳入观察性研究和随机对照试验)
研究设计与关键结果
- 研究类型:系统评价与Meta分析,纳入14项研究(10项观察性研究、4项RCT),共695例脓毒症患者。
- 主要终点28天死亡率:oXiris组较其他滤器组降低(OR 0.53;95%CI 0.36-0.77,p=0.001)。
- 次要终点ICU住院时间:oXiris组缩短(WMD -1.91;95%CI -2.56至-1.26,p<0.001)。
- 次要终点:SOFA评分、去甲肾上腺素剂量、IL-6和乳酸水平及7天、14天死亡率在oXiris组更低。
- 90天死亡率、ICU和医院死亡率及住院时间在两组间无显著差异。
- 质量评估:10项观察性研究质量中等至高(平均NOS评分7.8);4项RCT偏倚风险均不明确。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入观察性研究和随机对照试验,采用GRADE评估证据确定性。
- 所有结局证据确定性为低或极低,原因包括原始研究设计主要为观察性研究、纳入的RCT偏倚风险不明确且样本量小。
- 作者结论:oXiris滤器在脓毒症CRRT中可能降低28天、7天和14天死亡率、乳酸水平、SOFA评分、去甲肾上腺素剂量并缩短ICU住院时间,但由于证据质量低或极低,oXiris滤器的有效性仍不确定。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,脓毒症患者CRRT中使用oXiris滤器可能降低28天、7天和14天死亡率、乳酸水平、SOFA评分、去甲肾上腺素剂量并缩短ICU住院时间,但证据质量低或极低,有效性仍不确定。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The oXiris is a novel filter for continuous renal replacement therapy (CRRT) featuring an adsorption coating to adsorb endotoxins and remove inflammatory mediators. Given that no consensus has been reached on its potential benefits in treating sepsis, a meta-analysis was conducted to assess its impact on the clinical outcomes of this patient population.
METHODS: Eleven databases were retrieved to find relevant observational studies and randomized controlled trials. The Newcastle-Ottawa Scale and the Cochrane Risk of Bias Tool were used to assess the quality of the included studies. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) process was employed to assess the certainty of evidence. The 28-day mortality was the primary outcome. Secondary outcomes were 7-, 14-, and 90-day mortality, length of intensive care unit (ICU) and hospital stay, ICU and hospital mortality, norepinephrine (NE) dose, interleukin-6 (IL-6) and lactate levels, and Sequential Organ Failure Assessment (SOFA) score.
RESULTS: The meta-analysis, pooling data from 14 studies, involving 695 patients, showed significant reductions in 28-day mortality [odds ratio (OR) 0.53; 95% confidence interval (CI) 0.36-0.77, p = 0.001] and length of ICU stay [weighted mean difference (WMD) - 1.91; 95% CI - 2.56 to - 1.26, p < 0.001)] in patients with sepsis using the oXiris filter compared to other filters. Besides, the SOFA score, NE dose, IL-6 and lactate levels, and 7- and 14-day mortalities were lower in the oXiris group. However, the 90-day mortality, ICU and hospital mortality, and length of hospital stay were comparable. The quality assessment of the ten observational studies indicated intermediate to high quality (average Newcastle-Ottawa score: 7.8). However, all four randomized controlled trials (RCTs) had an unclear risk of bias. The evidence for all outcomes had a low or very low level of certainty because the original study design was mainly observational studies and the RCTs included had an unclear risk of bias and a small sample size.
CONCLUSION: The treatment with the oXiris filter during CRRT in sepsis patients may be associated with lower 28-, 7-, and 14-day mortalities, lactate levels, SOFA score, NE dose, and shorter length of ICU stay. However, due to the low or very low quality of evidence, the effectiveness of oXiris filters was still uncertain. Besides, no significant difference was observed for the 90-day mortality, ICU and hospital mortality, and length of hospital stay.
参考来源
- Wang G, He Y, Guo Q, et al. Continuous renal replacement therapy with the adsorptive oXiris filter may be associated with the lower 28-day mortality in sepsis: a systematic review and meta-analysis. Crit Care. 2023. PMID: 37424026. doi:10.1186/s13054-023-04555-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。